These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31303524)

  • 1. Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions.
    Seale AC; Baker CJ; Berkley JA; Madhi SA; Ordi J; Saha SK; Schrag SJ; Sobanjo-Ter Meulen A; Vekemans J
    Vaccine; 2019 Aug; 37(35):4877-4885. PubMed ID: 31303524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for preventing infant invasive GBS disease through maternal vaccination.
    Madhi SA; Dangor Z
    Vaccine; 2017 Aug; 35(35 Pt A):4457-4460. PubMed ID: 28237500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.
    Vekemans J; Crofts J; Baker CJ; Goldblatt D; Heath PT; Madhi SA; Le Doare K; Andrews N; Pollard AJ; Saha SK; Schrag SJ; Smith PG; Kaslow DC
    Vaccine; 2019 May; 37(24):3190-3198. PubMed ID: 31031031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?
    Lawn JE; Bianchi-Jassir F; Russell NJ; Kohli-Lynch M; Tann CJ; Hall J; Madrid L; Baker CJ; Bartlett L; Cutland C; Gravett MG; Heath PT; Ip M; Le Doare K; Madhi SA; Rubens CE; Saha SK; Schrag S; Sobanjo-Ter Meulen A; Vekemans J; Seale AC
    Clin Infect Dis; 2017 Nov; 65(suppl_2):S89-S99. PubMed ID: 29117323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
    Madhi SA; Dangor Z; Heath PT; Schrag S; Izu A; Sobanjo-Ter Meulen A; Dull PM
    Vaccine; 2013 Aug; 31 Suppl 4():D52-7. PubMed ID: 23973347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against group B streptococcus.
    Berardi A; Cassetti T; Creti R; Vocale C; Ambretti S; Sarti M; Facchinetti F; Cose S; ; Heath P; Le Doare K
    Ital J Pediatr; 2020 Oct; 46(1):160. PubMed ID: 33115542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.
    Carreras-Abad C; Cochet M; Hall T; Ramkhelawon L; Khalil A; Peregrine E; Vinayakarao L; Sivarajan S; Hamid R; Planche T; Sheridan E; Winchester S; Plumb J; Djennad A; Andrews N; Le Doare K; Heath P
    Health Technol Assess; 2019 Dec; 23(67):1-40. PubMed ID: 31855555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
    Kobayashi M; Schrag SJ; Alderson MR; Madhi SA; Baker CJ; Sobanjo-Ter Meulen A; Kaslow DC; Smith PG; Moorthy VS; Vekemans J
    Vaccine; 2019 Nov; 37(50):7307-7314. PubMed ID: 28017431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.
    Seale AC; Bianchi-Jassir F; Russell NJ; Kohli-Lynch M; Tann CJ; Hall J; Madrid L; Blencowe H; Cousens S; Baker CJ; Bartlett L; Cutland C; Gravett MG; Heath PT; Ip M; Le Doare K; Madhi SA; Rubens CE; Saha SK; Schrag SJ; Sobanjo-Ter Meulen A; Vekemans J; Lawn JE
    Clin Infect Dis; 2017 Nov; 65(suppl_2):S200-S219. PubMed ID: 29117332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?
    Oster G; Edelsberg J; Hennegan K; Lewin C; Narasimhan V; Slobod K; Edwards MS; Baker CJ
    Vaccine; 2014 Aug; 32(37):4778-85. PubMed ID: 24992717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group B Streptococcus: Trials and Tribulations.
    Davies HG; Carreras-Abad C; Le Doare K; Heath PT
    Pediatr Infect Dis J; 2019 Jun; 38(6S Suppl 1):S72-S76. PubMed ID: 31205250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.
    Giorgakoudi K; O'Sullivan C; Heath PT; Ladhani S; Lamagni T; Ramsay M; Al-Janabi H; Trotter C
    Vaccine; 2018 Nov; 36(46):7033-7042. PubMed ID: 30293765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa.
    Russell LB; Kim SY; Cosgriff B; Pentakota SR; Schrag SJ; Sobanjo-Ter Meulen A; Verani JR; Sinha A
    Vaccine; 2017 Dec; 35(49 Pt B):6905-6914. PubMed ID: 29129451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States.
    Kim SY; Nguyen C; Russell LB; Tomczyk S; Abdul-Hakeem F; Schrag SJ; Verani JR; Sinha A
    Vaccine; 2017 Oct; 35(45):6238-6247. PubMed ID: 28951085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B Streptococcus vaccine.
    Job MJ; Kim D; Acosta F; Valera S; Fernandez A; Laycock KM; Ratner AJ; Steenhoff AP; Feemster K; Geoghegan S
    Vaccine; 2024 Sep; 42(22):126169. PubMed ID: 39126829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness.
    Procter SR; Gonçalves BP; Paul P; Chandna J; Seedat F; Koukounari A; Hutubessy R; Trotter C; Lawn JE; Jit M
    PLoS Med; 2023 Mar; 20(3):e1004068. PubMed ID: 36917564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.
    Heyderman RS; Madhi SA; French N; Cutland C; Ngwira B; Kayambo D; Mboizi R; Koen A; Jose L; Olugbosi M; Wittke F; Slobod K; Dull PM
    Lancet Infect Dis; 2016 May; 16(5):546-555. PubMed ID: 26869376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.
    Dzanibe S; Madhi SA
    Expert Rev Vaccines; 2018 Jul; 17(7):635-651. PubMed ID: 29961350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches.
    Absalon J; Simon R; Radley D; Giardina PC; Koury K; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2022 Dec; 18(1):2037350. PubMed ID: 35240933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.